Genasense (oblimersen sodium) is an antisense oligonucleotide drug (a drug that targets expression of specific proteins). It inhibits production of Bcl-2, a protein made by cancer cells that is thought to block apoptosis (programmed cell death). By reducing the expression of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current treatments in causing cancer cell death. A new trial combining Genasense with Gleevec began at MD Anderson in January 2006.
More information about the drug may be found at the Genta website : http://www.genta.com/genta/Products/genasense.html
For information on the trial combining Gleevec with Genasense, “Oblimersen and Imatinib Mesylate In Treating Patients With Advanced Gastrointestinal Stromal Tumors That Can Not Be Removed By Surgery,” see this link: